Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001341875 | SCV001535771 | uncertain significance | not provided | 2020-10-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces leucine with valine at codon 766 of the TRPC6 protein (p.Leu766Val). The leucine residue is highly conserved and there is a small physicochemical difference between leucine and valine. This variant is present in population databases (rs201466403, ExAC 0.001%). This variant has not been reported in the literature in individuals with TRPC6-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). |
Fulgent Genetics, |
RCV002499678 | SCV002783093 | uncertain significance | Focal segmental glomerulosclerosis 2 | 2021-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002546943 | SCV003630042 | uncertain significance | Inborn genetic diseases | 2022-06-13 | criteria provided, single submitter | clinical testing | The c.2296C>G (p.L766V) alteration is located in exon 9 (coding exon 9) of the TRPC6 gene. This alteration results from a C to G substitution at nucleotide position 2296, causing the leucine (L) at amino acid position 766 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |